Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P01HL040962 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
eBACH is a randomized intervention to determine the effects of aerobic exercise on brain structure and function, as well as to determine how exercise-induced training effects relate to cardiovascular function via related brain changes.
Aim 1: To determine the neurobiology of exercise and cardiovascular factors: (1A) Body- to -Brain hypothesis: Exercise -induced changes in peripheral markers of cardiovascular health (e.g., cardiorespiratory fitness, peripheral vascular function) will precede and partly explain (statistically mediate) some of the exercise -induced changes in functional and structural features of areas defining visceral control circuits. (1B) Brain- to -Body hypothesis: Exercise -induced changes in functional and structural features of areas defining visceral control circuits precede and partly explain (statistically mediate) consequent changes in autonomic and neuroendocrine mediators of cardiovascular function that are under neural regulation, including baro-reflex sensitivity and heart rate variability. Aim 2: To determine the neurobiology of exercise self--reported correlates of cardiovascular function: (2A) Exercise will induce changes in visceral control areas engaged by functional magnetic resonance imaging (fMRI) tasks, and these changes will partly explain exercise- induced reductions in cardiovascular responsivity to challenges in daily life. (2B) Exercise will induce changes in visceral control areas engaged by an functional magnetic resonance imaging (fMRI) emotion processing and regulation paradigm, and these changes will partly explain exercise- induced improvements in affect measured in daily life by EMA and by conventional self- report instruments. The public health significance of this research is that it is designed to more precisely define and refine neurobiological targets to improve cardiovascular function and health.
Because of disruptions due to COVID-19, the study was placed into a compromised position that required conservation of funds and resources, resulting in a narrowing of focus and an abbreviated assessment protocol that limited the scale and scope of the longitudinal assessments and also reduced the sample size. As such, several of the secondary outcomes that were pre-specified were moved to "other pre-specified" during the course of the project.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aerobic Exercise Group | Experimental | This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting. |
|
| Physical Activity & Health Information Group | Active Comparator | This is the control group. Participants will engage in daily life monitoring every 6 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aerobic Exercise Group | Behavioral | Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Hippocampal Volume | Magnetic Resonance Imaging (MRI) will be used to measure the structure of the brain. Segmentation algorithms applied to structural MRI images will be used to compute the volume of the hippocampus in particular, which will be evaluated for change over the course of the trial. | Baseline & 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Systolic Blood Pressure Responses to Behavioral Tasks | Average systolic blood pressure will be computed during a resting baseline period and during the performance of two behavioral tasks, (1) a Stroop color-word interference task and (2) a multi-source interference task. Mean baseline levels of systolic blood pressure will be subtracted from mean levels averaged across the two tasks to compute response scores, and changes in task-response scores will be evaluated over the course of the trial. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in fMRI | Changes in task invoked activity will be measured during an emotion regulation task. | Baseline & 12 months |
| Change in Reappraisal and Suppression Scores | Participants will complete the Emotion Regulation Questionnaire (ERQ). They rate how strongly they agree with 10 statements and emotion regulation abilities are calculated by their responses. A minimum score would be 10 and a maximum score would be 70, with 70 indicating superior emotion regulation abilities. |
Inclusion Criteria:
Exclusion Criteria:
Current use of prescribed blood pressure medication - participants who regularly use blood pressure medication will be excluded from the study.
Self-reported chronic psychotic illness (schizophrenia, bipolar disorder) or neurological disorder (Parkinson's disease, dementia, MCI) - the eBACH study will exclude anyone who self-reports that they experience schizophrenia, bipolar disorder or parkinson's, dementia, or mild cognitive impairment.
Current pregnancy or plans to become pregnant over the next year - any woman who is pregnant via the pregnancy test at the baseline visit will be excluded from the study. A pregnancy test will also be given at the MRI visit and this will be repeated at 6-months (if applicable) and 12-months.
Self-reported prior heart attack, stroke, bypass surgery, angioplasty, congestive heart failure, arrhythmia (cardiac rhythm problems) - any person that reports that they have any of the health conditions listed above will be excluded from the study.
Severe hypertension (sbp/dbp greater than/or equal to 160/100)
Cancer - potential participants who have received treatment in the last 12 months for cancer, including radiation or chemotherapy will be excluded from the study. Although, if a potential participant who had non-melanoma skin cancer will be allowed to enroll in eBACH.
Liver disease - any person who has had hepatitis B or C, liver failure or Cirrhosis will be excluded from the study.
Kidney disease - potential participants who indicated they have chronic kidney failure, have undergone dialysis, or have had a kidney transplant will not be eligible to participant in the eBACH study.
Type 1 diabetes and/or insulin treatment
Lung disease requiring drug treatment (any medication usage 3x/week in the last 2 weeks for chronic obstructive pulmonary disease (COPD), emphysema, asthma)
Non fluency in English - speaking/reading English everyday for <10 years
Nightshift work - the eBACH study for the purposes of the EMA monitoring will exclude any participants who work more than 12 night shifts in the last year, or participants who work more than one night shift per month on average. This is defined as a period of work in which half or more of the hours worked are between midnight and 8:00 in the morning.
MRI incompatable
Suspected alcohol use disorder - for the eBACH study alcohol use disorder is defined as having five or more drinks at one time three times or more per week.
Those who are otherwise unable to meet the requirements of the study (persons whose employment or personal situation will not permit momentary interruptions required for electronic diary and ambulatory data)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kirk I Erickson, PhD | University of Pittsburgh | Principal Investigator |
| Peter Gianaros, PhD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37968003 | Derived | Molina Hidalgo C, Collins AM, Crisafio ME, Grove G, Kamarck TW, Kang C, Leckie RL, MacDonald M, Manuck SB, Marsland AL, Muldoon MF, Rasero J, Scudder MR, Velazquez-Diaz D, Verstynen T, Wan L, Gianaros PJ, Erickson KI. Effects of a laboratory-based aerobic exercise intervention on brain volume and cardiovascular health markers: protocol for a randomised clinical trial. BMJ Open. 2023 Nov 15;13(11):e077905. doi: 10.1136/bmjopen-2023-077905. |
Not provided
Not provided
The data from this study will be made available to outside investigators under a data-sharing agreement. The data will be available to outside investigators after publication of the primary aims and at completion of quality control assessments and data organization. The investigators expect that the data from this study will result in interest from internal and external investigators for secondary analysis and ancillary projects.
Will be made available after study investigators have published summary data and primary aims results. Will be available for unlimited amount of time.
Data requests will be approved by the PI and Co-PI. Requests can be made by contacting the study coordinator.
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Aerobic Exercise Group | This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting. Aerobic Exercise Group: Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps. |
| FG001 | Physical Activity & Health Information Group | This is the control group. Participants will engage in daily life monitoring every 6 weeks. Physical Activity & Health Information Group: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Aerobic Exercise Group | This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting. Aerobic Exercise Group: Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Hippocampal Volume | Magnetic Resonance Imaging (MRI) will be used to measure the structure of the brain. Segmentation algorithms applied to structural MRI images will be used to compute the volume of the hippocampus in particular, which will be evaluated for change over the course of the trial. | All randomized participants were included in intention-to-treat (ITT) analyses. | Posted | Least Squares Mean | 95% Confidence Interval | mm^3 | Baseline & 12 months |
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Aerobic Exercise Group | This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting. Aerobic Exercise Group: Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Tumor | Surgical and medical procedures | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiovascular | Vascular disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Kirk I. Erickson | AdventHealth Research Institute | 4125763724 | Kirk.Erickson@adventhealth.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 2, 2021 | Jan 24, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
130 individuals between the ages of 26 and 58 will be randomly assigned to one of two groups; Aerobic Exercise group or Physical Activity and Health Information group. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week over a 12-month period. Both groups will be asked to wear activity monitors every 6 weeks. Both groups will have fitness testing and cardiovascular assessments completed at baseline, 6 months (optional) and following the completion of the 12-month intervention.
Not provided
Not provided
Neither the investigator, nor outcomes assessors will know participants' group assignment. Participants will be instructed to refrain from speaking about their group's activities when visiting the lab for 6 month (if applicable) and follow-up assessments.In addition, special care was taken to ensure that non-blinded laboratory staff (i.e. staff member notifying participants of their group assignments, staff monitoring the intervention) are not located in the same proximity in the laboratory, further preventing accidental unblinding.
|
| Physical Activity & Health Information Group | Behavioral | This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits. |
|
| Baseline & 12 months |
| Change in Heart Rate Variability (HRV) | Heart rate variability will be computed from inter-beat intervals derived from electrocardiographic recordings while participants rest in the seated position. Average heart rate variability values from the recording period will be assessed for their change over the trial. Here, we report the natural log-transformed variance of high-frequency (HF) heart rate variability. | Baseline & 12 months |
| Baseline, 6-month (if applicable) & 12 months |
| Change in Perceived Stress Scale (PSS) | This will be calculated via the PSS 4-item scale. Scores are calculated by averaging responses from 10 questions with a minimum score of 0 and a maximum score of 40. 40 indicates more stress. | Baseline, 6-month (if applicable) & 12 months |
| Change in Self-esteem | Participants will complete a questionnaire related to self-esteem via the Rosenberg Self Esteem Scale. All items are answered using a 4-point Likert scale format ranging from strongly agree to strongly disagree. Sum scores for all 10 items are calculated with items 2, 5, 6, 8, 9 being reverse scored. Higher scores indicate higher self-esteem. | Baseline, 6-month (if applicable) & 12 months |
| Change in Blood Pressure | An average systolic blood pressure (SBP) will be calculated for an average over all baseline, 6-month (if applicable) and 12-month visits. | Baseline, 6-month (if applicable), & 12 months |
| Change in Cardiorespiratory Fitness | Fitness is assessed by maximal graded exercise testing. Oxygen uptake (VO2) will be measured from expired air samples taken at 15s intervals until a peak VO2, the highest VO2, is attained at the point of test termination due to symptom limitation and/or volitional exhaustion. | Baseline, 6-month (if applicable), & 12-month |
| Change in Fasting Glucose. | Blood will be drawn at 3 time points throughout the intervention starting at baseline to measure changes in fasting glucose. | Baseline, 6-month (if applicable) & 12 month |
| Change in Insulin Resistance. | Blood will be drawn at 3 time points throughout the intervention starting at baseline to measure changes in insulin resistance. | Baseline, 6-month (if applicable) & 12 month |
| Mediation | The outcome will be measured by whether the statistical mediation model that contains brain and peripheral physiological mediators is significant. By definition such a model must contain multiple outcome variables, but the outcome here isn't a measurable outcome but rather whether the statistical model with these variables reaches statistical significance. | Baseline, 6 month (if applicable) and 12 month. |
| Change in Heart Rate | An average heart rate will be calculated for an average over all baseline, 6-month (if applicable) and 12-month visits. | Baseline, 6-month (if applicable), & 12 months |
| Change in Daily Life Ecological Monitoring Assessment (EMA) | Participants will complete several questions on a smart phone at various times throughout the day based on a prompt to learn more about positive and negative affect. An average positive and negative affect score will be computed. | Baseline & 12 months |
| Change in Daily Life SBP Reactivity | Participants will have their blood pressure taken while answering questions about daily stressors and an average SBP score will be computed over the course of the wear period. | Baseline & 12 months |
| Change in Negative and Positive Affect | This will be calculated via scores from the Positive and Negative Affect Scale. Scores can range from 1 to 100, with 1 meaning less positive affect and 100 meaning more positive affect. | Baseline & 12 months |
| Change in Baroreflex Sensitivity (BRS) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. BRS will be derived in part from the EKG signal. | Baseline & 12 months |
| Change in Pulse Wave Velocity (PWV) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. PWV will be derived in part from the EKG signal. | Baseline & 12 months |
| Change in Vasodilation (Reactive Hyperemia) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. Vasodilation (reactive hyperemia) will be derived in part from the EKG signal. | Baseline & 12 months |
| Change in Brain Activity | MRI will be used to measure changes in brain activity including task invoked activation patterns. | Baseline & 12 months |
| Change in Resting State Connectivity | MRI will be used to measure changes in functional connectivity during rest. | Baseline & 12 months |
| Change in Cortical Thickness. | MRI will be used to measure cortical thickness. Measured in mm3. | Baseline & 12 months |
| Change in Cortical Volume. | MRI will be used to measure cortical volume. Measured in mm3. | Baseline & 12 months |
| BG001 | Physical Activity & Health Information Group | This is the control group. Participants will engage in daily life monitoring every 6 weeks. Physical Activity & Health Information Group: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| VO2peak | Peak oxygen uptake (VO2peak) is the highest VO2 value obtained during the maximal test and represents the measure of cardiorespiratory fitness used in this study. | Mean | Standard Deviation | mL/kg/min |
|
| OG001 | Physical Activity & Health Information Group | This is the control group. Participants will engage in daily life monitoring every 6 weeks. Physical Activity & Health Information Group: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits. |
|
|
| Secondary | Change in Systolic Blood Pressure Responses to Behavioral Tasks | Average systolic blood pressure will be computed during a resting baseline period and during the performance of two behavioral tasks, (1) a Stroop color-word interference task and (2) a multi-source interference task. Mean baseline levels of systolic blood pressure will be subtracted from mean levels averaged across the two tasks to compute response scores, and changes in task-response scores will be evaluated over the course of the trial. | Randomized participants who had baseline systolic blood pressure measures available were included in intention-to-treat (ITT) analyses. | Posted | Least Squares Mean | 95% Confidence Interval | mmHg | Baseline & 12 months |
|
|
|
| Secondary | Change in Heart Rate Variability (HRV) | Heart rate variability will be computed from inter-beat intervals derived from electrocardiographic recordings while participants rest in the seated position. Average heart rate variability values from the recording period will be assessed for their change over the trial. Here, we report the natural log-transformed variance of high-frequency (HF) heart rate variability. | Randomized participants who had heart rate variability measures available at baseline were included in intention-to-treat (ITT) analyses. | Posted | Least Squares Mean | 95% Confidence Interval | ln[ms²] | Baseline & 12 months |
|
|
|
| Other Pre-specified | Change in fMRI | Changes in task invoked activity will be measured during an emotion regulation task. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Reappraisal and Suppression Scores | Participants will complete the Emotion Regulation Questionnaire (ERQ). They rate how strongly they agree with 10 statements and emotion regulation abilities are calculated by their responses. A minimum score would be 10 and a maximum score would be 70, with 70 indicating superior emotion regulation abilities. | Not Posted | Baseline, 6-month (if applicable) & 12 months | Participants |
| Other Pre-specified | Change in Perceived Stress Scale (PSS) | This will be calculated via the PSS 4-item scale. Scores are calculated by averaging responses from 10 questions with a minimum score of 0 and a maximum score of 40. 40 indicates more stress. | Not Posted | Baseline, 6-month (if applicable) & 12 months | Participants |
| Other Pre-specified | Change in Self-esteem | Participants will complete a questionnaire related to self-esteem via the Rosenberg Self Esteem Scale. All items are answered using a 4-point Likert scale format ranging from strongly agree to strongly disagree. Sum scores for all 10 items are calculated with items 2, 5, 6, 8, 9 being reverse scored. Higher scores indicate higher self-esteem. | Not Posted | Baseline, 6-month (if applicable) & 12 months | Participants |
| Other Pre-specified | Change in Blood Pressure | An average systolic blood pressure (SBP) will be calculated for an average over all baseline, 6-month (if applicable) and 12-month visits. | Not Posted | Baseline, 6-month (if applicable), & 12 months | Participants |
| Other Pre-specified | Change in Cardiorespiratory Fitness | Fitness is assessed by maximal graded exercise testing. Oxygen uptake (VO2) will be measured from expired air samples taken at 15s intervals until a peak VO2, the highest VO2, is attained at the point of test termination due to symptom limitation and/or volitional exhaustion. | Not Posted | Baseline, 6-month (if applicable), & 12-month | Participants |
| Other Pre-specified | Change in Fasting Glucose. | Blood will be drawn at 3 time points throughout the intervention starting at baseline to measure changes in fasting glucose. | Not Posted | Baseline, 6-month (if applicable) & 12 month | Participants |
| Other Pre-specified | Change in Insulin Resistance. | Blood will be drawn at 3 time points throughout the intervention starting at baseline to measure changes in insulin resistance. | Not Posted | Baseline, 6-month (if applicable) & 12 month | Participants |
| Other Pre-specified | Mediation | The outcome will be measured by whether the statistical mediation model that contains brain and peripheral physiological mediators is significant. By definition such a model must contain multiple outcome variables, but the outcome here isn't a measurable outcome but rather whether the statistical model with these variables reaches statistical significance. | Not Posted | Baseline, 6 month (if applicable) and 12 month. | Participants |
| Other Pre-specified | Change in Heart Rate | An average heart rate will be calculated for an average over all baseline, 6-month (if applicable) and 12-month visits. | Not Posted | Baseline, 6-month (if applicable), & 12 months | Participants |
| Other Pre-specified | Change in Daily Life Ecological Monitoring Assessment (EMA) | Participants will complete several questions on a smart phone at various times throughout the day based on a prompt to learn more about positive and negative affect. An average positive and negative affect score will be computed. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Daily Life SBP Reactivity | Participants will have their blood pressure taken while answering questions about daily stressors and an average SBP score will be computed over the course of the wear period. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Negative and Positive Affect | This will be calculated via scores from the Positive and Negative Affect Scale. Scores can range from 1 to 100, with 1 meaning less positive affect and 100 meaning more positive affect. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Baroreflex Sensitivity (BRS) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. BRS will be derived in part from the EKG signal. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Pulse Wave Velocity (PWV) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. PWV will be derived in part from the EKG signal. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Vasodilation (Reactive Hyperemia) | Participants will have electrodes placed on their skin to record an EKG as well as a blood pressure cuff on their arm. Vasodilation (reactive hyperemia) will be derived in part from the EKG signal. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Brain Activity | MRI will be used to measure changes in brain activity including task invoked activation patterns. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Resting State Connectivity | MRI will be used to measure changes in functional connectivity during rest. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Cortical Thickness. | MRI will be used to measure cortical thickness. Measured in mm3. | Not Posted | Baseline & 12 months | Participants |
| Other Pre-specified | Change in Cortical Volume. | MRI will be used to measure cortical volume. Measured in mm3. | Not Posted | Baseline & 12 months | Participants |
| 0 |
| 64 |
| 1 |
| 64 |
| 6 |
| 64 |
| EG001 | Physical Activity & Health Information Group | This is the control group. Participants will engage in daily life monitoring every 6 weeks. Physical Activity & Health Information Group: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits. | 0 | 66 | 0 | 66 | 0 | 66 |
| Musculoskeletal | Musculoskeletal and connective tissue disorders | Non-systematic Assessment | Bone fracture, back pain, ankle sprain |
|
Not provided
Not provided
Not provided